Showing 6,101 - 6,120 results of 17,946 for search 'significantly ((((larger decrease) OR (teer decrease))) OR (a decrease))', query time: 0.75s Refine Results
  1. 6101

    Image 1_Yacon root is a functional food beneficial for human health: a meta-analysis of clinical trials.pdf by Ling-Hui Pan (9341084)

    Published 2025
    “…The pooled results showed that YR significantly reduced BMI [SMD = −0.81, 95%CI (−1.54, −0.08)], decreased stool pH [SMD = −1.12, 95%CI (−1.61, −0.62)], softened stools [SMD = 0.94, 95%CI (0.08, 1.80)], facilitated defecation [SMD = 4.03, 95% CI (0.54, 7.52)], improved fiber consumption patterns [SMD = 0.58, 95%CI (0.18, −0.99)]. …”
  2. 6102

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  3. 6103

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  4. 6104

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  5. 6105

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  6. 6106

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  7. 6107
  8. 6108
  9. 6109
  10. 6110
  11. 6111
  12. 6112
  13. 6113
  14. 6114
  15. 6115
  16. 6116

    VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals. by G. Robert Aguilar (13889674)

    Published 2025
    “…<p>(<b>A</b>) In <i>hlh-17/31/32</i><sup>null</sup> mutants, VB2 adopts a VB1-like NeuroPAL <i>(otIs669)</i> coloring. …”
  17. 6117
  18. 6118

    Kaplan-Meier plot. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  19. 6119

    Characteristics of the study sample. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  20. 6120

    Multivariate associations with incident leprosy. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”